



**Institutional Review Board for Human Research (IRB)
Office of Research Integrity (ORI)
Medical University of South Carolina**

**Harborview Office Tower
19 Hagood Ave., Suite 601, MSC857
Charleston, SC 29425-8570
Federal Wide Assurance # 1888**

APPROVAL:

This is to certify that the research proposal **Pro00053742** entitled:

**Comparative Effectiveness of Pulmonary Embolism Prevention after Hip and Knee Replacement:
Balancing Safety and Effectiveness**

submitted by: **Vincent D. Pellegrini, MD**
Department: **ORTHOPAEDIC SURGERY - MUSC**
Sponsor: **PCORI**
Sponsor Protocol Version: **A**
Dated: **4/25/2016**

for consideration has been reviewed by **IRB-II - Medical University of South Carolina** and approved with respect to the study of human subjects as adequately protecting the rights and welfare of the individuals involved, employing adequate methods of securing informed consent from these individuals and not involving undue risk in the light of potential benefits to be derived therefrom.

No IRB member who has a conflicting interest was involved in the review or approval of this study, except to provide information as requested by the IRB.

Original Approval Date: **4/19/2016**
Approval Expiration: **4/18/2017**

Type: **Full IRB Review**

Chair, **IRB-II - Medical University of South Carolina**
Susan Sonne, PharmD*

Statement of Principal Investigator:

As previously signed and certified, I understand that approval of this research involving human subjects is contingent upon my agreement:

1. To report to the Institutional Review Board for Human Research (IRB) any adverse events or research related injuries which might occur in relation to the human research. I have read and will comply with IRB reporting requirements for adverse events.
2. To submit in writing for prior IRB approval any alterations to the plan of human research.
3. To submit timely continuing review reports of this research as requested by the IRB.
4. To maintain copies of all pertinent information related to the research activities in this project, including copies of informed consent agreements obtained from all participants.
5. To notify the IRB immediately upon the termination of this project, and/or the departure of the principal investigator from this Institution and the project.

***Electronic Signature:** *This document has been electronically signed by the IRB Chairman through the HSSC eIRB Submission System authorizing IRB approval for this study as described in this letter.*